TrialAnnals of oncology : official journal of the European Society for Medical Oncology2019

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.

Y Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.